Cargando…
Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: The hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeostasis in the lung with acute lung injury post COVID-19, and can promote lung repa...
Autores principales: | Bosteels, Cedric, Maes, Bastiaan, Van Damme, Karel, De Leeuw, Elisabeth, Declercq, Jozefien, Delporte, Anja, Demeyere, Bénédicte, Vermeersch, Stéfanie, Vuylsteke, Marnik, Willaert, Joren, Bollé, Laura, Vanbiervliet, Yuri, Decuypere, Jana, Libeer, Frederick, Vandecasteele, Stefaan, Peene, Isabelle, Lambrecht, Bart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273817/ https://www.ncbi.nlm.nih.gov/pubmed/32503663 http://dx.doi.org/10.1186/s13063-020-04451-7 |
Ejemplares similares
-
Correction to: Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial
por: Bosteels, Cedric, et al.
Publicado: (2020) -
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial
por: Maes, Bastiaan, et al.
Publicado: (2020) -
Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial
por: Maes, Bastiaan, et al.
Publicado: (2020) -
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial
por: Declercq, Jozefien, et al.
Publicado: (2020) -
Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent
por: Declercq, Jozefien, et al.
Publicado: (2022)